Biologic Therapy Market to record USD 226.61 Bn growth -- North America to account for 57% market share

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The "Biologic Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. The report expects the market size to grow by USD 226.61 billion between 2021 and 2026, accelerating at a CAGR of 11% during the forecast period. The report provides a comprehensive analysis of the competitive landscape, key product launches, major trends, and other important statistics. Download PDF Sample Report

The market is primarily driven by factors such as the strong R&D pipeline. In addition, the increasing incidence of chronic diseases and immunological disorders will have a positive impact on the growth of the market. However, the high cost of biologics is expected to reduce the growth potential in the market.

• By Product, the market is classified into antibody therapeutics, vaccines, cell therapy, gene therapy, and other therapies. The antibody therapeutics segment is the largest segment of the global biologic therapy market. The market will observe maximum revenue generation in the antibody therapies segment during the forecast period. The segment is driven by the increasing demand and sales of antibodies in the pharmaceutical industry.
• By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market. The region is home to several key vendors such as AbbVie, Elli Lilly, Merck, Pfizer, and Amgen. Besides, changes in lifestyle and increased consumption of alcohol and tobacco have increased the prevalence of various chronic diseases. In addition, the active participation of the government in providing reimbursements for some of the biologics, rising patient awareness about the benefits of the use of biologics, vendor collaborations, and the increased prevalence of chronic diseases in the US are contributing to the growth of the biologic therapeutics market in North America.

The biologic therapy market report provides complete insights on key vendors including AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA.

The global biologic therapeutics market is concentrated. The vendors are adopting organic and inorganic growth strategies such as new product launches and M&As to remain competitive in the market. For instance, in June 2020, AbbVie Inc. and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. Similarly, in June 2020, GlaxoSmithKline Plc announced a strategic partnership with IDEAYA Biosciences, Inc., in Synthetic Lethality, an emerging field in oncology.

The competitive scenario provided in the biologic therapy market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Request Sample Report Here

• Cancer Biologics Market by Product and Geography - Forecast and Analysis 2022-2026
• Biologics CDMO Market by Type and Geography - Forecast and Analysis 2022-2026

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 01: Parent market
• Exhibit 02: Market characteristics

• 2.2 Value chain analysis

3 Market Sizing

• 3.1 Market definition 
• Exhibit 03: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 04: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025
• Exhibit 05: Global - Market size and forecast 2020 - 2025 ($ billion)
• Exhibit 06: Global market: Year-over-year growth 2020 - 2025 (%)

• 3.5 Market by application

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 07: Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers 
• Exhibit 08: Bargaining power of buyers

• 4.3 Bargaining power of suppliers 
• Exhibit 09: Bargaining power of suppliers

• 4.4 Threat of new entrants 
• Exhibit 10: Threat of new entrants

• 4.5 Threat of substitutes 
• Exhibit 11: Threat of substitutes

• 4.6 Threat of rivalry 
• Exhibit 12: Threat of rivalry

• 4.7 Market condition 
• Exhibit 13: Market condition - Five forces 2020

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 14: Product - Market share 2020-2025 (%)

• 5.2 Comparison by Product 
• Exhibit 15: Comparison by Product

• 5.3 Antibody therapeutics - Market size and forecast 2020-2025 
• Exhibit 16: Antibody therapeutics - Market size and forecast 2020-2025 ($ billion)
• Exhibit 17: Sales of major monoclonal antibodies 2018-2020 ($ million)
• Exhibit 18: Antibody therapeutics - Year-over-year growth 2020-2025 (%)

• 5.4 Vaccines - Market size and forecast 2020-2025
• Exhibit 19: Vaccines - Market size and forecast 2020-2025 ($ billion)
• Exhibit 20: Vendors offering vaccines
• Exhibit 21: Vaccines - Year-over-year growth 2020-2025 (%)

• 5.5 Cell therapy - Market size and forecast 2020-2025
• Exhibit 22: Cell therapy - Market size and forecast 2020-2025 ($ billion)
• Exhibit 23: Cell therapy - Year-over-year growth 2020-2025 (%)

• 5.6 Gene therapy - Market size and forecast 2020-2025
• Exhibit 24: Gene therapy - Market size and forecast 2020-2025 ($ billion)
• Exhibit 25: Gene therapy - Year-over-year growth 2020-2025 (%)

• 5.7 Other therapies - Market size and forecast 2020-2025
• Exhibit 26: Other therapies - Market size and forecast 2020-2025 ($ billion)
• Exhibit 27: Other therapies - Year-over-year growth 2020-2025 (%)

• 5.8 Market opportunity by Product 
• Exhibit 28: Market opportunity by Product

6 Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 30: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison 
• Exhibit 31: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025
• Exhibit 32: North America - Market size and forecast 2020-2025 ($ billion)
• Exhibit 33: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025
• Exhibit 34: Europe - Market size and forecast 2020-2025 ($ billion)
• Exhibit 35: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025
• Exhibit 36: Asia - Market size and forecast 2020-2025 ($ billion)
• Exhibit 37: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025
• Exhibit 38: ROW - Market size and forecast 2020-2025 ($ billion)
• Exhibit 39: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries 
• Exhibit 40: Key leading countries

• 7.8 Market opportunity by geography 
• Exhibit 41: Market opportunity by geography ($ billion)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges 
• Exhibit 43: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Overview 
• Exhibit 44: Vendor landscape

• 9.2 Landscape disruption 
• Exhibit 45: Landscape disruption
• Exhibit 46: Industry risks

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 47: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 48: Market positioning of vendors

• 10.3 AbbVie Inc. 
• Exhibit 49: AbbVie Inc. - Overview
• Exhibit 50: AbbVie Inc. - Product and service
• Exhibit 51: AbbVie Inc. – Key news
• Exhibit 52: AbbVie Inc. - Key offerings

• 10.4 AstraZeneca Plc 
• Exhibit 53: AstraZeneca Plc - Overview
• Exhibit 54: AstraZeneca Plc - Product and service
• Exhibit 55: AstraZeneca Plc – Key news
• Exhibit 56: AstraZeneca Plc - Key offerings

• 10.5 Bristol-Myers Squibb Co. 
• Exhibit 57: Bristol-Myers Squibb Co. - Overview
• Exhibit 58: Bristol-Myers Squibb Co. - Product and service
• Exhibit 59: Bristol-Myers Squibb Co. – Key news
• Exhibit 60: Bristol-Myers Squibb Co. - Key offerings

• 10.6 F. Hoffmann-La Roche Ltd. 
• Exhibit 61: F. Hoffmann-La Roche Ltd. - Overview
• Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
• Exhibit 63: F. Hoffmann-La Roche Ltd. – Key news
• Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
• Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus

• 10.7 GlaxoSmithKline Plc 
• Exhibit 66: GlaxoSmithKline Plc - Overview
• Exhibit 67: GlaxoSmithKline Plc - Business segments
• Exhibit 68: GlaxoSmithKline Plc – Key news
• Exhibit 69: GlaxoSmithKline Plc - Key offerings
• Exhibit 70: GlaxoSmithKline Plc - Segment focus

• 10.8 Johnson and Johnson Inc. 
• Exhibit 71: Johnson and Johnson Inc. - Overview
• Exhibit 72: Johnson and Johnson Inc. - Business segments
• Exhibit 73: Johnson and Johnson Inc. – Key news
• Exhibit 74: Johnson and Johnson Inc. - Key offerings
• Exhibit 75: Johnson and Johnson Inc. - Segment focus

• 10.9 Merck and Co. Inc. 
• Exhibit 76: Merck and Co. Inc. - Overview
• Exhibit 77: Merck and Co. Inc. - Business segments
• Exhibit 78: Merck and Co. Inc. – Key news
• Exhibit 79: Merck and Co. Inc. - Key offerings
• Exhibit 80: Merck and Co. Inc. - Segment focus

• 10.10 Novartis AG 
• Exhibit 81: Novartis AG - Overview
• Exhibit 82: Novartis AG - Business segments
• Exhibit 83: Novartis AG – Key news
• Exhibit 84: Novartis AG - Key offerings
• Exhibit 85: Novartis AG - Segment focus

• 10.11 Pfizer Inc. 
• Exhibit 86: Pfizer Inc. - Overview
• Exhibit 87: Pfizer Inc. - Business segments
• Exhibit 88: Pfizer Inc. – Key news
• Exhibit 89: Pfizer Inc. - Key offerings

• 10.12 Sanofi SA 
• Exhibit 90: Sanofi SA - Overview
• Exhibit 91: Sanofi SA - Business segments
• Exhibit 92: Sanofi SA – Key news
• Exhibit 93: Sanofi SA - Key offerings
• Exhibit 94: Sanofi SA - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$ 
• Exhibit 95: Currency conversion rates for US$

• 11.3 Research methodology 
• Exhibit 96: Research Methodology
• Exhibit 97: Validation techniques employed for market sizing
• Exhibit 98: Information sources

• 11.4 List of abbreviations 
• Exhibit 99: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio